Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and olderAndres Forero‐Torres, Christopher A. Yasenchak, Beata Holkova et al.|Blood|2015Cited by 142
Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapyJonathan W. Friedberg, Christopher A. Yasenchak, Rodolfo Bordoni et al.|Blood|2023Cited by 42
Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to IxazomibSudhir Manda, Robert M. Rifkin, Saulius Girnius et al.|Clinical Lymphoma Myeloma & Leukemia|2020Cited by 16
Frontline Brentuximab Vedotin As Monotherapy or in Combination for Older Hodgkin Lymphoma PatientsChristopher A. Yasenchak, Jonathan W. Friedberg, Rodolfo Bordoni et al.|Blood|2020Cited by 16
A Phase 2 Study Of Single-Agent Brentuximab Vedotin For Front-Line Therapy Of Hodgkin Lymphoma In Patients Age 60 Years and Above: Interim ResultsChristopher A. Yasenchak, Andres Forero‐Torres, Robert Chen et al.|Blood|2013Cited by 5